Form 4: SpringWorks Therapeutics Director Daniel Lynch Sells 400 Shares

Director Daniel Lynch sold 400 shares of SpringWorks Therapeutics (SWTX) common stock at $60 per share on February 14, 2025, according to a Form 4 filing.

Summary

• On February 14, 2025, Daniel Lynch, a director of SpringWorks Therapeutics, Inc. (SWTX), sold 400 shares of common stock at a price of $60 per share.
• Following the transaction, Lynch directly owns 130,544 shares of SpringWorks Therapeutics.
• The sale was executed under a pre-arranged trading plan (Rule 10b5-1) adopted on May 3, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Daniel Lynch, Form 4, Director, Stock Sale, Rule 10b5-1, Insider Trading